About the Study

Currently, there is no standard treatment for people who been exposed to the virus that causes COVID-19. People living with individuals who have been diagnosed with COVID-19 are especially at risk of being infected. This study, the Index Individuals Companion Study, will look at which factors may increase or decrease the likelihood of COVID-19 passing from one person to another within a household.

While we know that some people continue to experience symptoms or complications of COVID-19 weeks or months after their diagnosis, we still know very little about the long term consequences of COVID-19 infection. This study will also look at how often persistence or delayed onset of symptoms and complications occurs, what those symptoms and complications are, and if people that experience them are also more likely to have detectable virus long after their diagnosis.

This research study is conducted remotely by the University of Washington and the Fred Hutchinson Cancer Research Center. The study aims to recruit up to 2,000 people from across the United States.

To qualify for this study, participants must be 10 years of age or older, have been diagnosed with COVID-19, and have a household member who is participating in the Regeneron monoclonal antibody study.

Reimbursement

The Index Individuals Companion Study is conducted remotely, and participants complete all study visits and activities from their home. Including the enrollment visit, participants will complete up to four visits, with assistance from staff. Participants will be reimbursed $200 upon completion of all study activities.

Study Funders

The study is funded by the COVID-19 Prevention Trials Network (CoVPN), which was established by Institute of Allergy and Infectious Disease, Division of AIDS within the National Institutes of Health.

UW Medicine and Fred Hutchinson Cancer Research Center are part of the COVID-19 Prevention Network.